sales@dcchemicals.com
Lipid 43
Formulation & Performance
Formulation & Performance
Study-specific compositions, preparation conditions and experimental outcomes for Lipid 43.
Patent PDF reviewed, including the TMF30 composition, particle-size table, administration method and tissue-luminescence table.
1. Formulations and component amounts
Reported composition and calculated mass are separate. Molecular-weight inputs use the current catalog values; DMG-PEG2000 is fixed initially at 2507. Edit inputs only when using a verified alternative material.
TMF30
mol%WO2024109794A1, Table 3, printed p.130
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| Lipid 43 | 46.300 | 65.2423 | 61.2280 | ||
| DOPE | 9.400 | 13.2457 | 9.8552 | ||
| Cholesterol | 42.700 | 60.1695 | 23.2645 | ||
| DMG-PEG2000 | 1.600 | 2.2546 | 5.6523 |
Calculated total: 100.0000 mg lipid. RNA, solvent and process loss are excluded.
How component weights are calculated
For total lipid mass M (mg), molar parts rᵢ and molecular weight MWᵢ: component mass = M × rᵢ × MWᵢ / Σ(r × MW). Component amount (µmol) = component mass (mg) × 1000 / MWᵢ. Molar parts are normalized only for the displayed percentage. The calculation does not infer N/P or RNA dose.
2. Preparation and experimental setup
| Parameter | Reported procedure / limitation | Source |
|---|---|---|
| Formulation identity | TMF30 contains compound 43; it is not a generic formulation for every lipid in the patent. | Table 3 |
| Preparation cross-reference | The patent states TMF17–TMF53 follow the TMF2 preparation with the Table 3 component substitutions. Exact TMF2 mixing/buffer parameters are not reproduced in this revision. | Paragraph [0511], printed p.129 |
| RNA ratio / N/P | Not transcribed from a verified preparation passage; no inferred N/P is supplied. | Preparation cross-reference requires completion |
| Animal reporter assay | Female ICR mice, 6–8 weeks; retro-orbital intravenous administration, 0.5 mg/kg RNA; luciferin 150 mg/kg before imaging. | Paragraph [0517], printed p.132 |
3. Particle characterization
| Measurement / batch | Reported result | Evidence context |
|---|---|---|
| TMF30 hydrodynamic size | 210.60 ± 1.83 nm | Table 4, printed p.132; replicate/statistical basis not specified in the transcribed table |
| TMF30 PDI | 0.136 ± 0.018 | Table 4 |
| Encapsulation / apparent pKa | Not established in the reviewed TMF30 table | No value inferred |
4. Performance by experiment
| Experiment and dose | Readout and comparator | Result and source |
|---|---|---|
| Spleen reporter expression ICR mice; luciferase RNA; intravenous 0.5 mg/kg | Readout: 4 h after dosing Comparator: TMF17, DODAP-based formulation with the same listed helper ratios | TMF30 spleen flux 1.31 × 10⁹ p/s; TMF17 1.45 × 10⁶ p/s. These are tissue expression signals, not percentages of injected particles.Table 5, printed p.134; n/statistical test not stated in the transcribed table |
| Liver reporter expression Same TMF30 reporter experiment | Readout: 4 h Comparator: TMF17 liver flux 1.69 × 10⁶ p/s | TMF30 liver flux 3.56 × 10⁷ p/s. Higher spleen signal does not imply absence of liver delivery.Table 5; paragraph [0517] |
| Spleen:liver selectivity Same assay; compare individual formulations | Readout: 4 h Comparator: TMF29 (compound 38): spleen 5.73 × 10⁸, liver 8.48 × 10⁶ p/s; reported ratio 69.5 | TMF30 reported ratio is 38.8; dividing its displayed mean fluxes gives 36.80 (calculated). TMF30 has greater absolute spleen flux than TMF29 but a lower reported spleen:liver ratio.Table 5; calculated ratio is identified separately |
5. Interpretation and unresolved details
- The patent-reported 38.8 ratio is retained as reported; the displayed means do not reproduce it exactly. The statistic underlying that ratio is not specified here.
- No universal “best lipid” ranking follows from these data: absolute spleen expression and spleen:liver selectivity rank formulations differently.
- This is patent-stage mouse reporter evidence. CAR expression, human performance and therapeutic efficacy are not established by the cited TMF30 table.
Results apply to the stated LNP composition, cargo, process, dose, route and model. LNP experimental measurements are not batch-release specifications for the isolated lipid.
6. References and data access
WO2024109794A1; PCT/CN2023/133178. Novel Lipids Used for Nucleic Acid Delivery and Lipid Nanoparticle Composition. Compound 43 / formulation TMF30.
https://patents.google.com/patent/WO2024109794A1/en
Download experiment table (CSV) · Open printable Formulation & Performance guide
Revision FP-20261022 · Source review: 22 October 2026 · DC Chemicals